Progressing or preserving, disease extent evolution in hospitalized patients with ulcerative colitis in China: a real-world study.

IF 3.9 3区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY
Therapeutic Advances in Gastroenterology Pub Date : 2025-06-04 eCollection Date: 2025-01-01 DOI:10.1177/17562848251339878
Yinghao Sun, Gechong Ruan, Mingyue Guo, Yuge Wei, Xiaoyin Bai, Wei Han, Bei Tan, Ji Li, Yue Li, Hong Yang, Jiaming Qian
{"title":"Progressing or preserving, disease extent evolution in hospitalized patients with ulcerative colitis in China: a real-world study.","authors":"Yinghao Sun, Gechong Ruan, Mingyue Guo, Yuge Wei, Xiaoyin Bai, Wei Han, Bei Tan, Ji Li, Yue Li, Hong Yang, Jiaming Qian","doi":"10.1177/17562848251339878","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Disease extent of ulcerative colitis (UC) is dynamic, often shows progression or regression over time. However, factors associated with disease progression in long-term follow-ups remain underexplored.</p><p><strong>Objectives: </strong>This study aimed to examine disease extent progression in Chinese patients in a long-term follow-up cohort and identify associated risk factors.</p><p><strong>Design: </strong>Retrospective analysis.</p><p><strong>Methods: </strong>We retrospectively analyzed 800 hospitalized UC patients from 1980 to 2021, and followed up to December 2023. The disease extent was categorized according to the Montreal classification. The Cox regression model was used to identify factors associated with progression.</p><p><strong>Results: </strong>At diagnosis, 19.1% had E1 (ulcerative proctitis), 29.8% had E2 (left-sided UC), and 51.1% had E3 (extensive UC). By the end of follow-up, the proportion of maximum disease extent of E3 cases increased to 74.9%, while E1 and E2 patients decreased to 6.6% and 18.5%, respectively. Cox regression analysis revealed that patients with a history of appendectomy before the onset of disease were at higher risk of disease progression in those initially diagnosed with E1. Lower usage of glucocorticoids, immunosuppressants, and biologics were found in progression to the E3 group than initial E3 group. Lower usage of immunosuppressants and biologics before progression were found in the progressed to E3 group than not progressed to E3 group.</p><p><strong>Conclusion: </strong>Disease extent progression was common in Chinese UC patients. We suggest the necessity of aggressive treatment strategies, especially for early-stage UC patients, to mitigate disease progression and reduce the risk of related complications.</p>","PeriodicalId":48770,"journal":{"name":"Therapeutic Advances in Gastroenterology","volume":"18 ","pages":"17562848251339878"},"PeriodicalIF":3.9000,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12138221/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Gastroenterology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/17562848251339878","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Disease extent of ulcerative colitis (UC) is dynamic, often shows progression or regression over time. However, factors associated with disease progression in long-term follow-ups remain underexplored.

Objectives: This study aimed to examine disease extent progression in Chinese patients in a long-term follow-up cohort and identify associated risk factors.

Design: Retrospective analysis.

Methods: We retrospectively analyzed 800 hospitalized UC patients from 1980 to 2021, and followed up to December 2023. The disease extent was categorized according to the Montreal classification. The Cox regression model was used to identify factors associated with progression.

Results: At diagnosis, 19.1% had E1 (ulcerative proctitis), 29.8% had E2 (left-sided UC), and 51.1% had E3 (extensive UC). By the end of follow-up, the proportion of maximum disease extent of E3 cases increased to 74.9%, while E1 and E2 patients decreased to 6.6% and 18.5%, respectively. Cox regression analysis revealed that patients with a history of appendectomy before the onset of disease were at higher risk of disease progression in those initially diagnosed with E1. Lower usage of glucocorticoids, immunosuppressants, and biologics were found in progression to the E3 group than initial E3 group. Lower usage of immunosuppressants and biologics before progression were found in the progressed to E3 group than not progressed to E3 group.

Conclusion: Disease extent progression was common in Chinese UC patients. We suggest the necessity of aggressive treatment strategies, especially for early-stage UC patients, to mitigate disease progression and reduce the risk of related complications.

中国溃疡性结肠炎住院患者的进展或维持,疾病程度演变:一项真实世界的研究
背景:溃疡性结肠炎(UC)的疾病范围是动态的,常随时间进展或消退。然而,在长期随访中,与疾病进展相关的因素仍未得到充分研究。目的:本研究旨在通过长期随访队列研究中国患者的疾病进展程度,并确定相关的危险因素。设计:回顾性分析。方法:回顾性分析1980年至2021年住院的800例UC患者,随访至2023年12月。根据蒙特利尔分类法对疾病程度进行分类。采用Cox回归模型确定与进展相关的因素。结果:诊断时,19.1%为E1(溃疡性直肠炎),29.8%为E2(左侧UC), 51.1%为E3(广泛性UC)。随访结束时,E3患者最大病变程度比例上升至74.9%,E1和E2患者分别下降至6.6%和18.5%。Cox回归分析显示,发病前有阑尾切除术史的患者在最初诊断为E1的患者中疾病进展的风险更高。与初始E3组相比,在E3组进展中发现糖皮质激素、免疫抑制剂和生物制剂的使用较低。进展到E3组进展前免疫抑制剂和生物制剂的使用率低于未进展到E3组。结论:中国UC患者疾病程度进展普遍。我们建议采取积极的治疗策略,特别是对于早期UC患者,以减缓疾病进展并降低相关并发症的风险。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Therapeutic Advances in Gastroenterology
Therapeutic Advances in Gastroenterology GASTROENTEROLOGY & HEPATOLOGY-
CiteScore
6.70
自引率
2.40%
发文量
103
审稿时长
15 weeks
期刊介绍: Therapeutic Advances in Gastroenterology is an open access journal which delivers the highest quality peer-reviewed original research articles, reviews, and scholarly comment on pioneering efforts and innovative studies in the medical treatment of gastrointestinal and hepatic disorders. The journal has a strong clinical and pharmacological focus and is aimed at an international audience of clinicians and researchers in gastroenterology and related disciplines, providing an online forum for rapid dissemination of recent research and perspectives in this area. The editors welcome original research articles across all areas of gastroenterology and hepatology. The journal publishes original research articles and review articles primarily. Original research manuscripts may include laboratory, animal or human/clinical studies – all phases. Letters to the Editor and Case Reports will also be considered.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信